CR7698A - Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos - Google Patents
Nuevos derivados de benzoimidazol utiles como agentes antiproliferativosInfo
- Publication number
- CR7698A CR7698A CR7698A CR7698A CR7698A CR 7698 A CR7698 A CR 7698A CR 7698 A CR7698 A CR 7698A CR 7698 A CR7698 A CR 7698A CR 7698 A CR7698 A CR 7698A
- Authority
- CR
- Costa Rica
- Prior art keywords
- benzoimidazol
- new
- compounds
- formula
- antiproliferative agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invencion se refiere a compuestos de formula 1 y a sales, profarmacos y solvatos farmaceuticamente aceptables de los mismos, donde R1,R2,R3 y R4 son como se han definido anteriormente. La invencion tambien se refiere a procedimientos para tratar el crecimiento celular anormal, tal como cancer, en mamiferos administrando los compuestos de formula 1 y a composiciones farmaceuticas para tratar tales trastornos que contienen los compuestos de formula 1. La invencion tambien se refiere a procedimientos para preparar los compuestos de formula 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40652402P | 2002-08-28 | 2002-08-28 | |
US41704702P | 2002-10-08 | 2002-10-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR7698A true CR7698A (es) | 2007-11-23 |
Family
ID=31981411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR7698A CR7698A (es) | 2002-08-28 | 2005-02-22 | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
Country Status (41)
Country | Link |
---|---|
US (1) | US7071337B2 (es) |
EP (1) | EP1594858B1 (es) |
JP (1) | JP4551771B2 (es) |
KR (2) | KR20070086768A (es) |
CN (1) | CN1319966C (es) |
AP (1) | AP2005003237A0 (es) |
AR (1) | AR041055A1 (es) |
AT (1) | ATE445610T1 (es) |
AU (1) | AU2003250499B2 (es) |
BR (1) | BRPI0313942C1 (es) |
CA (1) | CA2495577C (es) |
CR (1) | CR7698A (es) |
CU (1) | CU23413B7 (es) |
CY (1) | CY1110580T1 (es) |
DE (1) | DE60329715D1 (es) |
DK (1) | DK1594858T3 (es) |
DO (1) | DOP2003000694A (es) |
EA (1) | EA008448B1 (es) |
EC (1) | ECSP055633A (es) |
ES (1) | ES2333219T3 (es) |
GE (1) | GEP20064005B (es) |
HK (1) | HK1078571A1 (es) |
HN (1) | HN2003000257A (es) |
HR (1) | HRP20050191B1 (es) |
IL (1) | IL166832A (es) |
IS (1) | IS2738B (es) |
MA (1) | MA27389A1 (es) |
MX (1) | MXPA05001256A (es) |
MY (1) | MY139357A (es) |
NO (1) | NO20051303L (es) |
NZ (1) | NZ538427A (es) |
OA (1) | OA12916A (es) |
PA (1) | PA8580301A1 (es) |
PE (1) | PE20050131A1 (es) |
PL (1) | PL377678A1 (es) |
PT (1) | PT1594858E (es) |
RS (1) | RS20050180A (es) |
SI (1) | SI1594858T1 (es) |
TW (1) | TW200407131A (es) |
UY (1) | UY27952A1 (es) |
WO (1) | WO2004020431A2 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1641780T3 (da) * | 2003-06-24 | 2009-02-02 | Pfizer Prod Inc | Fremgangsmåder til fremstilling af 1-[(benzimidazol-1yl)quinolin-8-yl]-piperidin-4-ylamin-derivater |
BRPI0509580A (pt) * | 2004-03-30 | 2007-11-27 | Pfizer Prod Inc | combinações de inibidores de transdução de sinal |
GB0411421D0 (en) * | 2004-05-21 | 2004-06-23 | Glaxo Group Ltd | Novel compounds |
MX2007004183A (es) * | 2004-10-07 | 2007-06-07 | Pfizer Prod Inc | Derivados de benzoimidazol utiles como agentes antiproliferacion. |
EP2444419A1 (en) | 2005-04-26 | 2012-04-25 | Pfizer Inc. | P-Cadherin antibodies |
PE20080035A1 (es) | 2005-09-07 | 2008-01-30 | Amgen Fremont Inc | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina |
AU2007251282A1 (en) | 2006-05-09 | 2007-11-22 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
WO2008124323A1 (en) | 2007-04-03 | 2008-10-16 | Array Biopharma Inc. | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
NZ589622A (en) * | 2008-05-21 | 2012-10-26 | Incyte Corp | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
CN103189378B (zh) | 2010-09-02 | 2016-03-02 | 默克专利股份公司 | 作为lpa受体拮抗剂的吡唑并吡啶酮衍生物 |
GB201103578D0 (en) | 2011-03-02 | 2011-04-13 | Sabrepharm Ltd | Dipyridinium derivatives |
TWI569799B (zh) * | 2012-09-21 | 2017-02-11 | 安羅格製藥股份有限公司 | 抑制組成型活性磷酸化flt3激酶的方法 |
US10835525B2 (en) | 2012-09-26 | 2020-11-17 | Arog Pharmaceuticals, Inc. | Method of inhibiting mutant C-KIT |
US11642340B2 (en) | 2012-09-26 | 2023-05-09 | Arog Pharmaceuticals, Inc. | Method of inhibiting mutant C-KIT |
JP6042157B2 (ja) * | 2012-09-26 | 2016-12-14 | アログ・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニーArog Pharmaceuticals,LLC | 変異型c−kitの阻害方法 |
BR112015016282A2 (pt) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals Inc | crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado |
US10463658B2 (en) | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
TN2017000168A1 (en) * | 2014-10-31 | 2018-10-19 | Genoscience Pharma | Substituted 2,4 diamino-quinoline as new anticancer agents |
GB2543550A (en) | 2015-10-21 | 2017-04-26 | Hox Therapeutics Ltd | Peptides |
US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
SI3452465T1 (sl) * | 2016-05-04 | 2021-04-30 | Genoscience Pharma | Substituirani derivati 2,4-diamino-kinolina za uporabo v zdravljenju proliferativnih bolezni |
AU2017353925A1 (en) | 2016-11-02 | 2018-09-27 | Arog Pharmaceuticals, Inc. | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations |
CN107382984B (zh) * | 2017-08-24 | 2020-07-10 | 扬州市三药制药有限公司 | 一种治疗白血病药物的制备方法 |
CN107382983B (zh) * | 2017-08-24 | 2020-08-07 | 扬州市三药制药有限公司 | 一种治疗白血病药物的合成方法 |
CN110840893A (zh) | 2018-12-13 | 2020-02-28 | 安罗格制药有限责任公司 | 含克莱拉尼的药物组合物及其用途 |
US11471451B2 (en) | 2019-08-19 | 2022-10-18 | Arog Pharmaceuticals, Inc. | Uses of crenolanib |
CN113024435B (zh) * | 2019-12-09 | 2022-06-17 | 苏州恩华生物医药科技有限公司 | 连双环结构sigma-1受体抑制剂 |
US11713310B2 (en) | 2020-07-20 | 2023-08-01 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
CN116234549A (zh) * | 2020-08-05 | 2023-06-06 | 总医院公司 | 盐诱导激酶抑制剂 |
US11524006B2 (en) | 2020-09-17 | 2022-12-13 | Arog Pharmaceuticals, Inc. | Crenolanib for treating TRK kinase associated proliferative disorders |
US11969420B2 (en) | 2020-10-30 | 2024-04-30 | Arog Pharmaceuticals, Inc. | Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders |
CN113683594B (zh) * | 2021-09-07 | 2022-12-27 | 曲靖师范学院 | 一种喹啉-苯并咪唑盐类化合物及其合成方法和应用 |
JP2023063189A (ja) | 2021-10-22 | 2023-05-09 | アログ・ファーマシューティカルズ・インコーポレイテッド | 以前の治療に対して再発性/不応性のflt3突然変異増殖性障害を治療するためのクレノラニブ |
WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
CN114409632B (zh) * | 2022-02-22 | 2024-04-30 | 北京鲲达宇科技有限公司 | 2-取代氨基-3-苯并咪唑取代的喹啉衍生物及其制备方法与应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
AU744939B2 (en) | 1997-09-26 | 2002-03-07 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
UA75055C2 (uk) * | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
EP1233956A4 (en) * | 1999-11-30 | 2006-07-05 | Univ Leland Stanford Junior | BRYOSTATIN ANALOGUE, SYNTHETIC METHODS AND USES |
JP2008002005A (ja) * | 2006-06-21 | 2008-01-10 | Shimada Shoji Kk | 衣服用パッド |
-
2003
- 2003-08-12 PA PA8580301A patent/PA8580301A1/es unknown
- 2003-08-14 DK DK03791110T patent/DK1594858T3/da active
- 2003-08-14 JP JP2004569727A patent/JP4551771B2/ja not_active Expired - Lifetime
- 2003-08-14 EA EA200500174A patent/EA008448B1/ru not_active IP Right Cessation
- 2003-08-14 PT PT03791110T patent/PT1594858E/pt unknown
- 2003-08-14 GE GEAU2003008665 patent/GEP20064005B/en unknown
- 2003-08-14 DE DE60329715T patent/DE60329715D1/de not_active Expired - Lifetime
- 2003-08-14 CA CA 2495577 patent/CA2495577C/en not_active Expired - Lifetime
- 2003-08-14 OA OA1200500059A patent/OA12916A/en unknown
- 2003-08-14 NZ NZ538427A patent/NZ538427A/en not_active IP Right Cessation
- 2003-08-14 KR KR1020077014809A patent/KR20070086768A/ko not_active Application Discontinuation
- 2003-08-14 PL PL37767803A patent/PL377678A1/pl not_active Application Discontinuation
- 2003-08-14 AU AU2003250499A patent/AU2003250499B2/en not_active Ceased
- 2003-08-14 AT AT03791110T patent/ATE445610T1/de active
- 2003-08-14 BR BRPI0313942A patent/BRPI0313942C1/pt not_active IP Right Cessation
- 2003-08-14 KR KR20057003493A patent/KR100816166B1/ko active IP Right Grant
- 2003-08-14 SI SI200331687T patent/SI1594858T1/sl unknown
- 2003-08-14 AP AP2005003237A patent/AP2005003237A0/xx unknown
- 2003-08-14 EP EP20030791110 patent/EP1594858B1/en not_active Expired - Lifetime
- 2003-08-14 WO PCT/IB2003/003634 patent/WO2004020431A2/en active Application Filing
- 2003-08-14 ES ES03791110T patent/ES2333219T3/es not_active Expired - Lifetime
- 2003-08-14 MX MXPA05001256A patent/MXPA05001256A/es active IP Right Grant
- 2003-08-14 CN CNB038206218A patent/CN1319966C/zh not_active Expired - Lifetime
- 2003-08-19 DO DO2003000694A patent/DOP2003000694A/es unknown
- 2003-08-25 PE PE2003000864A patent/PE20050131A1/es active IP Right Grant
- 2003-08-25 HN HN2003000257A patent/HN2003000257A/es unknown
- 2003-08-26 AR ARP030103073 patent/AR041055A1/es unknown
- 2003-08-26 US US10/648,151 patent/US7071337B2/en active Active
- 2003-08-26 UY UY27952A patent/UY27952A1/es not_active Application Discontinuation
- 2003-08-26 MY MYPI20033225 patent/MY139357A/en unknown
- 2003-08-27 TW TW92123585A patent/TW200407131A/zh unknown
-
2005
- 2005-01-20 IS IS7660A patent/IS2738B/is unknown
- 2005-02-10 IL IL166832A patent/IL166832A/en active IP Right Grant
- 2005-02-14 CU CU20050031A patent/CU23413B7/es not_active IP Right Cessation
- 2005-02-22 CR CR7698A patent/CR7698A/es unknown
- 2005-02-28 EC ECSP055633 patent/ECSP055633A/es unknown
- 2005-02-28 HR HRP20050191AA patent/HRP20050191B1/hr not_active IP Right Cessation
- 2005-02-28 MA MA28124A patent/MA27389A1/fr unknown
- 2005-03-14 NO NO20051303A patent/NO20051303L/no not_active Application Discontinuation
- 2005-08-14 RS YUP-2005/0180A patent/RS20050180A/sr unknown
- 2005-11-18 HK HK05110348A patent/HK1078571A1/xx not_active IP Right Cessation
-
2009
- 2009-11-30 CY CY20091101249T patent/CY1110580T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR7698A (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
UY28135A1 (es) | Derivados de pirimidina para el tratamiento de crecimiento celular anormal | |
CU23132A3 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
PA8480101A1 (es) | Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos | |
SV1999000252A (es) | Derivados biciclicos sustituidos utiles como agentes contra el cancer ref.pc10113abcz | |
ECSP024393A (es) | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal | |
AR029634A1 (es) | Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento | |
PA8490601A1 (es) | Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos. | |
ECSP045483A (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso | |
PA8480201A1 (es) | Derivados de quinilin-2-ona utiles como agentes contra el cancer | |
UY26872A1 (es) | Derivados de la 4- fenil piridina | |
UY26086A1 (es) | Procedimientos e intermedios para preparar compuestos anticancerosos | |
UY27685A1 (es) | Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso | |
ECSP003793A (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
ECSP993260A (es) | Derivados biciclicos sustituidos utiles como agentes contra el cancer | |
UY26460A1 (es) | Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos. | |
ECSP993117A (es) | Derivados de quinolin -2 - ona utiles como agentes contra el cancer | |
UY26785A1 (es) | Derivados bicíclicos sustituidos para el tratamiento del crecimiento celular anormal | |
ECSP993118A (es) | Derivados de quinolin -2 -ona alquinilsustituidos utiles como agentes anticancerosos | |
UY27557A1 (es) | Procedimiento para la preparación de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal. | |
ECSP992984A (es) | Derivados de isotiazol utiles como agentes anticancerosos | |
DOP2003000595A (es) | Indolil-urea derivado de tienopiridinas utiles como agentes antiangionicos,y procedimientos para su uso | |
DOP2003000786A (es) | Derivados biciclicos para el tratamiento del crecimiento celular anormal. | |
ECSP003347A (es) | Derivados quinolin - 2- ona sustituidos con heteroarilo utiles como agentes anticancerigenos | |
UY28131A1 (es) | Derivados biciclicos para el tratamiento del crecimiento celular anormal |